Alcohol Pharmacotherapy for HIV+ Prisoners

Conditions

AIDS | Alcohol Dependence | Hazardous Drinking | Human Immunodeficiency Virus | Problem Drinking

What is the purpose of this trial?

This is a randomized controlled trial of injectable intramuscular naltrexone (XR-NTX) versus intramuscular placebo among HIV-infected prisoners meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for alcohol dependence or problem drinking, who are transitioning to the community and seeking treatment to prevent relapse to alcohol use. We hypothesize that extended release naltrexone (XR-NTX) will result in improved HIV outcomes (lower log10 HIV-1RNA levels and higher CD4 count) as well as improved alcohol treatment outcomes, and reduced drug/sex HIV related risk behaviors and decreased rates of reincarceration.



Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Yale University
Dates:
August 2010
Last Updated:
August 4, 2011
Study HIC#:
0908005572

Clinicaltrials.gov ID: NCT01077310